Sort
21,453 grants matching “tuberculosis”
Clinical Impact of Anti-TB Drug Levels and M. Tuberculosis Susceptibility
$129,870Scott K Heysell · University Of Virginia · K23 · FY2013 · AI
Clinical Impact of Anti-TB Drug Levels and M. Tuberculosis Susceptibility
$129,870Scott K Heysell · University Of Virginia · K23 · FY2015 · AI
Clinical Impact of Anti-TB Drug Levels and M. Tuberculosis Susceptibility
$129,870Scott K Heysell · University Of Virginia · K23 · FY2014 · AI
Clinical Impact of Anti-TB Drug Levels and M. Tuberculosis Susceptibility
$129,870Scott K Heysell · University Of Virginia · K23 · FY2012 · AI
Clinical Impact of Anti-TB Drug Levels and M. Tuberculosis Susceptibility
$129,870Scott K Heysell · University Of Virginia · K23 · FY2016 · AI
Second Generation InSTIs for the Treatment of HIV-1 in patients with TB co-infection on Rifampicin-based Treatment in KwaZulu Natal, South Africa
$129,848Anushka Naidoo · Centre/Aids Programme/Res/South Africa · R01 · FY2023 · AI
Bedside-to-Bench Research Training for Pediatric Infectious Diseases Fellows
$129,733Mark R. Schleiss · University Of Minnesota · T32 · FY2013 · HD
Improving Pediatric Tb Diagnosis and Management in Tanzania
$129,707Tania A Thomas · University Of Virginia · K23 · FY2012 · AI
Identification of antimicrobial reagents against TB and ESKAPE pathogens from bacteria collected in Vietnam
$129,670Tuan Anh Tran · --Institute Of Marine Biochemistry · R01 · FY2021 · AI
Targeting non-coding RNAs as host-directed drug therapy for tuberculosis
$129,659Reto Guler · University Of Cape Town · R01 · FY2025 · AI
In depth characterization of Mtb specific HLA-E restricted human CD8+ T-cells
$129,605Tom Ottenhoff · Leiden University Medical Center · R21 · FY2017 · AI
Genetic/Immunological Basis of Tuberculosis and Anergy
$129,546Brigham And Women'S Hospital · K08 · FY2002 · HL
CORE--INTERNATIONAL
$129,540University Of California Los Angeles · P30 · FY2001 · AI
CORE--INTERNATIONAL
$129,540University Of California Los Angeles · P30 · FY2002 · AI
RESEARCH CORE
$129,466Robert Anders · University Of Texas El Paso · P20 · FY2009 · MD
Improving the control of multidrug-resistant tuberculosis through targeted screening and use of novel anti-tuberculosis drugs
$129,444Reza Yaesoubi · Yale University · K01 · FY2017 · AI
Defining Moxifloxacin as a First-line TB Drug
$129,330Eric L Nuermberger · Johns Hopkins University · K08 · FY2006 · AI
Defining Moxifloxacin as a First-line TB Drug
$129,330Eric L Nuermberger · Johns Hopkins University · K08 · FY2008 · AI
Defining Moxifloxacin as a First-line TB Drug
$129,330Eric L Nuermberger · Johns Hopkins University · K08 · FY2007 · AI
Improving Pediatric Tb Diagnosis and Management in Tanzania
$129,325Tania A Thomas · University Of Virginia · K23 · FY2013 · AI
Virology and Microbial Pathogenesis Core
$129,297David J McDonald · Case Western Reserve University · P30 · FY2014 · AI
Novel Ribostamycins and SAR Study of Ring III Aminosugar
$129,292Cheng-Wei T Chang · Utah State University · R01 · FY2008 · AI
Core B. Biochemistry and Enzymology
$129,279James C Sacchettini · Weill Medical Coll Of Cornell Univ · P01 · FY2021 · AI
Modeling approaches to prioritize TB prevention among people with HIV in Uganda
$129,222Jennifer M Ross · University Of Washington · K01 · FY2019 · AI
Pharmacology and Pharmacometrics Core
$129,210Eric L Nuermberger · Johns Hopkins University · P30 · FY2025 · AI